Tanezumab - Pfizer/Eli Lilly

Drug Profile

Tanezumab - Pfizer/Eli Lilly

Alternative Names: PF-04383119; PF-4383119; RI-624; RN-624

Latest Information Update: 28 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rinat Neuroscience
  • Developer Eli Lilly; Pfizer
  • Class Monoclonal antibodies; Non-opioid analgesics
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Back pain; Cancer pain; Musculoskeletal pain; Pain
  • Suspended Diabetic neuropathies
  • No development reported Postherpetic neuralgia

Most Recent Events

  • 18 Jul 2018 Adverse events data from the phase III TITRATION STUDY in Osteoarthritis released by Pfizer and Eli Lilly
  • 24 Jun 2018 Biomarkers information updated
  • 14 May 2018 Pfizer completes the phase III OA TITRATION STUDY trial for Musculoskeletal pain (associated with osteoarthritis of knee or hip) in USA, Canada and Puerto Rico (SC) (NCT02697773)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top